phase iii trial: pembrolizumab for patients w/ metastatic nsclc that expresses pd-1
Published 9 years ago • 1.3K plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
3:46
phase iii trial: pembrolizumab for patients w/ metastatic nsclc that expresses pd-1
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
2:56
keynote-010: pembrolizumab, anti-pd-1, for advanced nsclc with pd-l1 expression
-
0:35
dr. farago on the fda approval of pembrolizumab for lower pd-1 cutoff nsclc
-
3:10
pembrolizumab new option for firstline treatment of advanced lung cancer with high pdl-1 expression
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
4:51
lung cancer trial for patients with prior response to immunotherapy
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
5:58
lung cancer video library - liu - leading treatment options for patients with negative tumor pd l1
-
6:32
keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
-
4:39
chemotherapy pembrolizumab: a new standard of care?
-
1:57
keynote-010: pembrolizumab versus docetaxel in advanced pd-l1-positive nsclc